32 Likes, 1 Comments - Molecular & Cell Biology UCT (@mcb_uct) on Instagram: “Corrie "Cornelius" Gunter presenting his research on expressing porcine circovirus virus-like…”...
When it emerged that two people infected with monkeypox had travelled by plane through one of the world's busiest airports, a media storm arose, with irresponsible headlines and exaggerations of risks for others in the UK and across the globe. The two patients—currently recovering in specialist units in London and Liverpool, UK—probably contracted the infection, which produces symptoms such as fever, headache, malaise, and the typical smallpox-like vesicular rash, from animals in Nigeria, where there is an ongoing outbreak of the virus. The Nigeria Centre for Disease Control has recorded 262 suspected cases of monkeypox since the outbreak began in September, 2017, including 113 confirmed cases and seven deaths. The Nigerian outbreak is likely to be the result of a local zoonotic spillover event from the virus' natural hosts—rodents. The disease, caused by a virus of the Orthopox genus, is usually self-limiting—although it has a mortality rate of 1–10%.
On May 8, 2018, the USA withdrew from the Iran nuclear deal and re-imposed a list of sanctions that target Iran's economy and companies from third-party countries that continue to trade with Iran. Both US and non-US business partners have been winding down their economic activities in Iran. These sanctions will have a detrimental effect on the country's viral hepatitis elimination programme. In 2016, WHO adopted a resolution to eliminate viral hepatitis by 2030 by decreasing the incidence of chronic infection and mortality through improving interventions such as screening, universal vaccination, and access to antiviral therapies.1 However, these elimination targets are only achievable if sufficient resources are available. In Iran, viral hepatitis is the main cause of hepatocellular carcinoma,2 and almost 2 million people are infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).3 Data indicate that Iran is among the countries that are working towards elimination of HCV and is on track to decrease HBV prevalence to 1% or less by 2030.4 The HBV vaccines and antiviral medicines for HBV and HCV are produced domestically, but local manufacturing still relies on the importation of raw materials. Furthermore, the Iranian blood transfusion organisation imports all its viral hepatitis screening kits. Acquiring these supplies will be difficult if not impossible under a regime of economic sanctions.
A recent study by Johns Hopkins researchers look at the flu and what may explain why men recover faster. The study published in the journal Biology of Sex Di...
Author summary Spread of many RNA viruses in a population represents a competition between host immune responses and viral evolution. RNA viruses accumulate mutations in immunologically important regions to escape immune recognition in hosts previously exposed to infection, while the immune system...
Single-dose influenza drug baloxavirhas similar efficacy to oseltamivir, according to new data in the New England Journal of Medicine. Also today, the relati...
September 12, 2018 5:00 AMThere have been no cases of pilgrims returning from the haj with flu-like symptoms in Singapore, amid two haj-related health...
UCT Vaccinology Research Chair Professor Anna-Lise Williamson has been honoured with a gold medal from the SA Medical Research Council for her seminal scientific contributions.
The Thailand Department of Disease Control has reported 84,941 influenza cases through August 25, including 12 deaths. Provinces with the top five morbidity rates (cases per 100,000 population) were Bangkok, Chiangmai, Rayong, Phayao, and Ubonratchathani.
Reddit gives you the best of the internet in one place. Get a constantly updating feed of breaking news, fun stories, pics, memes, and videos just for you. Passionate about something niche? Reddit has thousands of vibrant communities with people that share your interests.
After years of spreading confusion about vaccines, the Five Star Movement and its governing partner, the League, have reduced vaccination proof to a...
Investment in health is an essential component of the FOCAC. Whereas some laud China's investment strategy, others deplore that gains to health are hard to track. Andrew Green reports. At this year's Forum on China-Africa Cooperation (FOCAC), Beijing pledged to build on previous commitments to improve health care on the continent, including promises to upgrade medical facilities, to invest in the Africa Centres for Disease Control and Prevention (Africa CDC), and to train medical specialists. However, with the China's investments in Africa plateauing this year, experts said they did not anticipate a dramatic expansion of health projects. Beijing announced US$60 billion in financial support to Africa at this month's FOCAC, including $15 billion in aid and $10 billion that the Chinese Government will encourage private industry to invest. The 2018 total matches that of 2015, although the previous amount included only government investments.
Author summary The Salicylic acid (SA)-mediated plant immunity plays a major role against diverse pathogens including viruses. However, the underlying SA-mediated virus resistance pathway is not fully understood.
A 64-year-old otherwise healthy virology professor comes to your office complaining of flu symptoms. She has had fever, cough, and sore throat for the last day or so that she attributes to one of her students. She has been furiously sanitizing her hands and comes to the office wearing a face mask. Being the savvy patient, she brings reverse transcriptase–polymerase chain reaction (RT-PCR) results that confirm she has influenza A virus (as does the student). She is febrile but hemodynamically stable with no signs of lower respiratory tract infection. She asks about available treatment options, explaining that she will be presenting at a conference tomorrow. How would you proceed? In this week’s NEJM, Hayden and colleagues report the results of two double-blind, randomized-controlled trials comparing single-dose baloxavir versus placebo or oseltamivir in patients with uncomplicated influenza in Japan and the United States during the 2015–2017 flu seasons. Baloxavir marboxil (Xofluza) is an important new addition to the armamentarium against flu because it represents a new class of antiviral drugs that target a different process than the other two classes available (amadantanes and neuraminidase inhibitors), and has antiviral activity against strains resistant to those agents. Baloxavir also has the advantage of requiring a single dose, as compared to 5 days of twice daily oseltamivir (Tamiflu). Baloxavir is a cap-dependent endonuclease inhibitor that blocks viral replication by blocking the initiation of mRNA synthesis (read more here). In the phase 3 trial (CAPSTONE-1), the investigators randomized 1436 patients (age range, 12–64 years) with uncomplicated flu to receive a single dose of baloxavir (40 mg), oseltamivir (75 mg twice daily for 5 days), or matching placebos (with those aged 12-19 assigned only to baloxavir or placebo). Uncomplicated flu was defined as fever ≥38.0°C, at least one systemic symptom and one respiratory symptom, and presentation with 48 hours of symptom onset. Pregnant women and those requiring hospitalization were excluded. The primary endpoint was the time until flu symptoms became absent or mild for at least 21.5 hours. The intention-to-treat infected population included only RT-PCR-positive patients. Roughly 85% of patients in the three treatment groups were infected with influenza A (H3N2) and most (77%) were recruited in Japan. The time to alleviation of symptoms was significantly shorter (by 26.5 hours) in the baloxavir group, when compared with the placebo group (median, 53.7 vs. 80.2 hours), and similar to the oseltamivir group (53.5 vs. 53.8 hours). Baloxavir was associated with significantly more rapid decline in potentially infectious viral load as compared to both oseltamivir and placebo. The rate of adverse events was similar in the three groups. Emergence of mutations conferring reduced baloxavir susceptibility occurred in fewer than 10% of baloxavir recipients, which prolonged time to resolution of symptoms by about 13 hours. Per CDC recommendations, only individuals with acute influenza who are at high risk of related complications (e.g., in a chronic care facility, pregnant, age ≥65 years) should receive antiviral treatment. Hence, the results of this trial are not likely to affect current practice or treatment of the professor described above. The importance of this study lies in the demonstration of the safety and efficacy of baloxavir for treatment of uncomplicated acute influenza in otherwise healthy patients. These encouraging results will form the basis for future study of baloxavir in higher risk populations, where its utility and future clinical indications may lie. Browse more From Pages to Practice » Tenzing T. Lama, MD, MScRes, is a resident physician in the Department of Anesthesiology and Pain Medicine at the University of Washington and a Fellow at the Ethics and Transformative Values Center at the Massachusetts Institute of Technology. He graduated from Harvard Medical School and Oxford.
AS CHINA’S agriculture authorities scramble to contain the spread of a pig-killing virus, experts worry that it could spread elsewhere in Asia. But the consequences of the disease at home are bad enough.
Plants have no eyes, no ears, no mouth and no hands. They do not have a brain or a nervous system. Muscles? Forget them. They’re stuck where they started, soaking up the sun and sucking up nutrients from the soil. And yet, when something comes around to eat them, they sense it.
A promising new cancer vaccine has shown the ability to ward off, and stop the return, of aggressive cancer cells.By adding a molecule called Diprovocim to a...
A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a "pre-pandemic" influenza vaccine is underway at Baylor College of Medicine in Houston (USA).
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.